If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Nanopore Technologies Regulatory News (ONT)

Share Price Information for Oxford Nanopore Technologies (ONT)

Share Price is delayed by 15 minutes
Get Live Data
120.40    -3.30 (-2.67%)
Bid:
120.20
Ask:
120.60
Spread: 0.40 (0.333%)
Market Cap: £1.17b
ONT Live PriceLast checked at - London Stock Exchange

Intraday Oxford Nanopore Technologies Share Chart

Agreement

1 Apr 2022 07:00

RNS Number : 8618G
Oxford Nanopore Technologies plc
01 April 2022
 

1 April 2022

Oxford Nanopore Technologies plc

Entry into settlement agreement with Department of Health and Social Care

The Department of Health and Social Care (DHSC) and Oxford Nanopore Technologies plc (ONT) reached an amicable resolution of the dispute relating to the contract dated 30 July 2020 for the supply of certain LamPORE™ devices and testing kits and associated services by ONT to DHSC. DHSC and ONT entered into a settlement agreement without any admission of liability, which included agreement as to the contract being brought to an end and includes a payment of £50 million in full of amounts due to ONT under the contract.

ONT expects the payment to be treated as non-recurring COVID-19 testing revenue during the fiscal year ended 31 December 2022. Therefore, ONT's prior guidance for Life Science Research Tools revenue in 2022 remains unchanged.

[ENDS]

Enquiries:

Investors

ir@nanoporetech.com 

Media

media@nanoporetech.com

oxfordnanoporetechnologies@tulchangroup.com

This announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU no. 596/2014), which forms part of English law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging the release of this announcement on behalf of the Company is Hannah Coote, Company Secretary of Oxford Nanopore Technologies plc.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGREANDFDAAAEFA
Date   Source Headline
21st Jul 20257:00 amRNSHalf Year Trading Update and Notice of Results
14th Jul 20256:00 pmRNSShare Incentive Plan - Director/PDMR Notification
4th Jul 20254:30 pmRNS-RPublication of 2024 Sustainability Report
1st Jul 20255:00 pmRNSIssue of Equity and Total Voting Rights
27th Jun 20258:30 amRNSHolding(s) in Company
18th Jun 20259:30 amRNSHolding(s) in Company
12th Jun 20254:00 pmRNSShare Incentive Plan - Director/PDMR Notification
11th Jun 20255:30 pmRNSHolding(s) in Company
5th Jun 20255:55 pmRNSChanges in Composition of Remuneration Committee
4th Jun 20251:00 pmRNSResult of AGM
3rd Jun 20257:00 amRNSIssue of Equity and Total Voting Rights
2nd Jun 20258:00 amRNSHolding(s) in Company
22nd May 20257:00 amRNS-RLondon Calling Technology Update
14th May 20253:00 pmRNSShare Incentive Plan - Director/PDMR Notification
1st May 20254:30 pmRNSIssue of Equity and Total Voting Rights
30th Apr 20256:15 pmRNSFounder LTIP - Director/PDMR Notification
30th Apr 20257:00 amRNSPublication of Annual Report and Notice of AGM
24th Apr 202512:00 pmRNSHolding(s) in Company
10th Apr 20252:00 pmRNSHolding(s) in Company
9th Apr 20252:00 pmRNSBlock listing Interim Review
9th Apr 202512:00 pmRNSOxford Nanopore and Cepheid collaboration
2nd Apr 20259:30 amRNSIssue of Equity and Total Voting Rights
26th Mar 20252:30 pmRNSDirector/PDMR Shareholding
14th Mar 20253:00 pmRNSSIP PDMR Notification - Correction
13th Mar 20253:00 pmRNSShare Incentive Plan - Director/PDMR Notification
12th Mar 20255:00 pmRNSDirector/PDMR Shareholding
6th Mar 20257:00 amRNSHolding(s) in Company
5th Mar 20255:34 pmRNSHolding(s) in Company
4th Mar 20257:00 amRNSAnnual results for the year ended 31 December 2024
3rd Mar 20255:00 pmRNSIssue of Equity and Total Voting Rights
19th Feb 20257:00 amRNSHolding(s) in Company
7th Feb 20253:00 pmRNSShare Incentive Plan - Director/PDMR Notification
4th Feb 202512:00 pmRNSHolding(s) in Company
3rd Feb 20255:30 pmRNSIssue of Equity and Total Voting Rights
13th Jan 20253:00 pmRNSSIP PDMR Notification and Correction
13th Jan 20257:00 amRNSFull Year Trading Update and Notice of Results
6th Jan 20255:00 pmRNSHolding(s) in Company
2nd Jan 20254:00 pmRNSIssue of Equity and Total Voting Rights
16th Dec 20244:30 pmRNSDirectorate Change - Appointment of SID
11th Dec 20243:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
9th Dec 202412:00 pmRNSHolding(s) in Company
2nd Dec 20245:45 pmRNSIssue of Equity and Total Voting Rights
28th Nov 20247:00 amRNSClass A LAT share - Director/PDMR Notification
27th Nov 20247:00 amRNSOxford Nanopore and UK Biobank collaboration
26th Nov 20247:00 amRNSProposed cancellation of LAT shares
21st Nov 20241:00 pmRNSHolding(s) in Company
12th Nov 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
11th Nov 20247:00 amRNSChanges to the senior leadership team
6th Nov 20247:00 amRNSApproval of the transfer of listing category
4th Nov 20249:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.